Radiotherapy to Consolidate Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This will be a pragmatic, phase II, registry-based cohort-multiple randomized controlled trial (cmRCT) embedded within an ongoing prospective cancer radiotherapy registry. Eligible patients are those with hormone-sensitive metastatic prostate cancer who have responded to systemic therapy, defined by the absence of PSA progression, and who are eligible for MDRT. All eligible subjects will be enrolled into the registry and followed longitudinally for oncologic and toxicity outcomes. From this registry, patients will be randomly selected (1:1) to be offered the experimental arm, which consists of MDRT delivered to metastatic sites identified on imaging in patients who have already initiated systemic therapy (Figure 1). Those not selected will continue to receive standard of care systemic therapy +/- standard of care radiotherapy if clinically indicated. Nor patients or physicians will be blinded. Following the initial course of MDRT, prostate-specific antigen (PSA) will be measured, with a minimum assessment at 3 months. This PSA value will be used to determine whether the PSA level has decreased below 0.2 ng/mL. If the PSA remains ≥ 0.2 ng/mL, repeat PSMA-PET will be performed, and a second course of MDRT will be delivered to consolidate residual metastatic lesions. In this phase II real-world randomized trial, we will determine if AnChoRing (Addition of MDRT for consolidation of response) sites of PSMA PET visible disease when responding to systemic therapy improves the proportion of patients achieving a PSA \< 0.2 ng/mL and extends failure-free survival compared to the standard of care.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Uczestnictwo w rejestrze PERa i losowy wybór do badania ANCHOR-Prostate
- •Rozpoznany rak prostaty z przerzutami wrażliwy na hormony, który odpowiada na leczenie
- •Brak wzrostu markerów PSA
- •Ogólny stan zdrowia pozwalający na udział w badaniu
- •Przerzuty nadające się do napromieniania
- •Pierwotny guz musi być wcześniej leczony operacyjnie lub radioterapią, bez wznowy
✗ Disqualifies
- •Planowane leczenie systemowe przerwane (tylko okresowe)
- •Planowana terapia za pomocą radioaktywnych ligandów
Simplified criteria — AI translation
Trial details
- Last updated (source)
- September 8, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
CRCHUM
Montreal, Canada
Trial contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.